Page 392 - Binder2

• Fight to preserve legacy delivery models.
• Lobby to limit reimbursement for home-
administered therapies.
• Frame edible biologics as “experimental” to protect
procedural turf.

But others will adapt—and thrive. These are the practices
that:

• Invest in biologic coaching and digital follow-up.
• Collaborate with local production sites.
• Leverage AI and immune literacy to offer more
personalized, outcomes-driven care.
• Embrace a leaner, less transactional business
model rooted in trust, outcomes, and long-term
patient relationships.

What Gets Valued, Gets Reimbursed

Ultimately, the edible biologics revolution will reveal how
distorted our healthcare incentives have become.

If a doctor spends 60 minutes helping a patient understand
their immune system and commit to a tolerogenic protocol,
they may be paid less than for administering a 15-minute
injection.

That isn’t just a reimbursement issue—it’s an ethical
misalignment.

If the future of biologics is:

• Durable
• Accessible

390